Yahoo Web Search

Search results

    • Rituximab Tied to Increased Infection Risk in RRMS

      Medscape· 1 day ago

      The B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.

    • Small Business - Picayune Item | Picayune Item

      The Picayune Item· 4 days ago

      FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease ...